Eli Lilly’s Zepbound eases obstructive sleep apnea in trials
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Studies in mice and monkeys showed that immune cells could be shepherded to produce antibodies that block a broad swath of HIV strains — a…
AbstractBackground and aims. Data describing the long-term efficacy, safety, and tolerability of inclisiran are limited. This was explored in ORION-8, an o
Jerry Seinfeld, award-winning comedian, actor, producer and author, delivered the commencement address during Duke’s 2024 university-wide commencement ceremo…
Molecular engineer Patrick Hsu and Arc Institute colleagues trained an AI model on vast troves of biological data from 80,000 genomes of bacteria and archaea.…
Recent readouts from early stage clinical trials show that what’s going into Phase 1 clinical trial is more successful, Powell said told the audience at…
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, maker of the weight loss drug Wegovy, is tops, according…
© 1993 AQUARIUS RECORDS & ĐORĐE BALAŠEVIĆZabranjeno svako kopiranje video i/ili audio snimaka i postavljanje na druge kanale!Pratite nas na:Zvanični sajt: ht…
Implantable cardioverter-defibrillators last longer, and interest in reliable leads with targeted lead placement is growing. The OmniaSecure™ defibrillation lead is a novel small-diameter, catheter-delivered lead…
Welcome to the May edition of the European Heart Journal: Acute Cardiovascular Care with an exhilarating fusion of groundbreaking research and enlightening
Empower healthcare professionals with the latest insights on cardiovascular health, tackling treatment disparities and optimizing prevention strategies. Stay abreast of evolving clinical evidence and address…